ABIOMED, Inc. (NASDAQ:ABMD) is reporting second quarter earnings results on Thursday 29th October 2020, before market open.
The consensus estimates from Thomson Reuters are income of $ 0.92 per share from $ 198.93 million in revenue.
For the full year, analysts predict revenues of $ 843.43 million, while looking forward to income of $ 4.48 per share.
Previous Quarter Performance
ABIOMED, Inc. outlined income for the first quarter of $ 0.58 per share, from the revenue of $ 164.85 million. Street analysts expected ABIOMED, Inc. to report income of $ 0.29 per share on revenue of $ 151.11 million for the first quarter. The bottom line results beat street analysts by $ 0.29 or 100.00 percent, at the same time, top line results outshined analysts by $ 13.74 million or 9.09 percent.
Stock Performance
Shares of ABIOMED, Inc. traded low $ -7.51 or -2.59 percent on Wednesday, reaching $ 283.00 with volume of 448.70 thousand shares. ABIOMED, Inc. has traded high as $ 290.30 and has cracked $ 279.84 on the downward trend
According to the previous trading day, closing price of $ 283.00, representing a 144.11 % increase from the 52 week low of $ 119.01 and a 8.99 % decrease over the 52 week high of $ 319.19.
The company has a market capital of $ 12.75 billion and is part of the Healthcare sector and Medical Appliances & Equipment industry.
Conference Call
ABIOMED, Inc. will be hosting a conference call at 8:00 AM eastern time on 29th October 2020, to discuss its 2Q21 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.abiomed.com
Abiomed, Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides continuum of care to heart failure patients.
